ALSO NOTED: Integra buys IsoTis for $49.3M; MannKind searches for insulin drug partner; and much more...

> Device maker Integra LifeSciences is buying IsoTis for $49.3 million. Release [1]

> MannKind told investors on Friday that it faced an uncertain delay in finding a partner for its inhalable insulin candidate [2], and investors responded Monday by taking a bite out of the developer's share price. Adding to the uncertainty surrounding the company, MannKind says it is delaying the release of its second-quarter report until Aug. 9 and that CFO Richard Anderson is retiring. The monumental failure of Pfizer's Exubera--an inhalable insulin drug--to find a market niche may be making potential partners particularly skittish. Report [3]

> KineMed has raised $15 million and plans to use the money to advance its lead drug candidate into clinical trials. Release [4]

> Bayer Thai and Schering (Bangkok) have merged. Report [5]

> Isotechnika announced that the FDA has granted fast track designation for its lead drug, ISA247. Release [6]

> Entelos has struck a deal with the FDA to create a computer model for drug-induced liver damage. Release [7]

> Abraxis BioScience has won regulatory approval to sell Oxytocin Injection in a 30 ml vial. Release [8]

> In 2006, Pharma racked up a multibillion-dollar marketing bill. FiercePharma [9]

> PricewaterhouseCoopers has released a study based on interviews with 185 top pharma execs in the Asia-Pacific region. The verdict? Not only are China, India, Singapore and their neighbors poised to become huge pharmaceuticals consumers, but big producers as well. FiercePharma [10]

And Finally… Drinking more than three cups of coffee a day may help women delay memory loss. Report [11]